Longevity · Explainer
ApoB vs LDL Cholesterol: Why the Newer Number Is Better
LDL-C measures the cholesterol inside the particles. ApoB counts the particles. Where they disagree, the particle count wins.
By Julien Malet, · Updated 2026-09-08
A standard lipid panel reports LDL-C — the amount of cholesterol carried by low-density lipoproteins. It is the number most people have been told to watch, and it is a decent proxy. ApoB is a better one, it costs a few dollars more, and it is often not ordered unless you ask.
The distinction
Cholesterol does not dissolve in blood, so it travels inside lipoprotein particles. Atherosclerosis begins when one of those particles crosses into an artery wall and gets retained there.
The key fact: it is the particle that lodges in the wall, not the cholesterol it happens to be carrying. And particles vary considerably in how much cholesterol each one holds.
Every atherogenic particle — LDL, VLDL, IDL, remnants, Lp(a) — carries exactly one apolipoprotein B molecule. So measuring ApoB counts the particles directly.
- LDL-C = how much cholesterol is in the cargo
- ApoB = how many trucks are on the road
Since risk tracks the number of trucks, ApoB is the more direct measure.
Where they disagree, and why it matters
Two people can have the same LDL-C and very different ApoB. If your particles are small and cholesterol-depleted, you need more of them to carry the same cholesterol — same LDL-C, higher particle count, higher risk.
This pattern — small dense LDL — clusters with insulin resistance, metabolic syndrome, type 2 diabetes and high triglycerides. Which means the people whose LDL-C most understates their risk are exactly the people at highest risk for other reasons. That is called discordance, and it is the practical argument for ApoB.
Mendelian randomisation and trial data support ApoB as the better predictor where the two disagree. Several lipid guidelines now list it as a preferred or reasonable alternative measure.
Non-HDL-C: the free version
If you cannot get ApoB, non-HDL cholesterol is a decent stand-in and it requires no extra test — it is on every lipid panel you have already had:
Non-HDL-C = total cholesterol − HDL-C
It captures cholesterol in all atherogenic particles, not just LDL, which makes it better than LDL-C alone and worse than ApoB. Free is a strong argument.
Targets
Interpretation depends on your overall risk, and that is a conversation with your doctor rather than an article. Broad orientation:
- ApoB under ~80 mg/dL is a commonly cited general target
- Under ~60–65 mg/dL for people at high cardiovascular risk or with established disease
- Population averages sit well above both, which is a statement about the population rather than about what is optimal
Lower is better across the range studied, and duration of exposure matters as much as level — cumulative particle-years, not a snapshot. This is why the number matters in your forties rather than only after an event.
Ask for Lp(a) once
While you are ordering, ask for lipoprotein(a) once in your life.
Lp(a) is a genetically determined, largely diet- and exercise-independent atherogenic particle. Roughly one in five people has an elevated level and almost none of them know. It is not on a standard panel, it does not need repeating because it barely changes, and a high result meaningfully changes how aggressively everything else should be managed.
One test, once, for information you cannot get any other way.
What moves ApoB
Diet: reducing saturated fat, and adding soluble fiber — see why fiber matters. Plant sterols have a modest effect.
Weight and exercise: improve the pattern, particularly the triglyceride/small-dense-LDL picture.
Medication: statins, ezetimibe and PCSK9 inhibitors lower ApoB substantially. This is where the large effect sizes live, and for people at real risk it is not a last resort.
Supplements: red yeast rice contains monacolin K, which is chemically the same as lovastatin — so it is an unregulated statin with unpredictable dosing, and it deserves to be treated as a drug rather than a supplement. Niacin lowers lipids but has not improved outcomes in trials. Fish oil lowers triglycerides more than ApoB.
What to actually do
At your next blood draw, ask for ApoB and, once, Lp(a). If ApoB is unavailable, calculate non-HDL-C from the panel you already have. Then discuss the results against your total risk rather than against a single threshold.
Full context in the biomarkers worth tracking.